Browse > Article

Effect of Pentoxifylline, a Phosphodiesterase Inhibitor, on Osteoclast Formation  

김민혜 (숙명여자대학교 약학대학)
전윤나 (숙명여자대학교 약학대)
임미정 (숙명여자대학교 약학대학)
Publication Information
YAKHAK HOEJI / v.48, no.3, 2004 , pp. 197-201 More about this Journal
Abstract
Phosphodiesterases (PDEs) are enzymes that degrade intracellular cAMP. In the present study, pentoxifylline, a PDE inhibitor, induced osteoclast formation in co-cultures of mouse bone marrow cells and calvarial osteoblasts. To address the involvement of the osteoclast differentiation factor TNF-related activation-induced cytokine (TRANCE, identical to RANKL, ODF, and OPGL), mouse bone marrow cells and calvarial osteoblasts were co-cultured with pentoxifylline in the presence of OPG, a decoy receptor for TRANCE. The osteoclastogenic effect of pentoxifylline was completely blocked by addition of OPG, suggesting that TRANCE is involved in the osteoclast formation induced by pentoxifylline, Northern blot analysis revealed that pentoxifylline significantly induced TRANCE mRNA expression in calvarial osteoblasts. These results suggests that pentoxifylline regulates TRANCE expression in osteoblasts, which in turn controls osteoclast formation.
Keywords
osteoblast; osteoclast; phosphodiesterase; TRANCE; pentoxifylline;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalach S., Cayani, E., Bartlett, F. S. 3rd, Frankel， W. N., Lee, S. Y. and Choi, Y. : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 , 25190 (1997)   DOI   ScienceOn
2 Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess , T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu,H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V.,Senaldi, G., Guo, J., Delaney, J. and Boyle, W.J. : Osteoprotegerin ligand is cytokine that regulates osteoclast differentiation and activation. Cell 93, 165 (1998)   DOI   ScienceOn
3 Fu, Q., Jilka, R. L., Manolagas, S. C. and O'Brien, C. A. : Parathyroid hormone stimulates receptor activator of NF-$\kappa$B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding pro-tein. J. Biol. Chem. 277, 48868 (2002)   DOI   ScienceOn
4 Kinoshita, T., Kobayashi, S., Ebara, S., Yoshimura, Y., Horiuchi, H., Tsutsumimoto, T., Wakabayashi, S. and Takaoka, K. : Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 27, 811 (2000)   DOI   ScienceOn
5 Miyamoto, K., Waki, Y., Horita, T., Kasugai, S. and Ohya, K. : Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem. Pharmacol. 54, 613 (1997)   DOI   PUBMED   ScienceOn
6 Tam, C. S., Heersche, J. N., Murray, T. M. and Parsons, J. A. : Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110, 506 (1982)   DOI   ScienceOn
7 Suda, T.，Takahashi，N., Udagawa, N., Jimi, E., Gillespie, M. T and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999)   DOI   ScienceOn
8 Essayan, D. M. : Cyclic nucleotide phosphodiesterases. J Allergy Clin. Immunol. 108, 671 (2001)   DOI   ScienceOn
9 Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T M., Hill, D., Pattison, W., Campbell, P. and Boyle, W. J. : Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309 (1997)   DOI   ScienceOn
10 Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A.,Moseley, J . M., Martin, T. J.and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endoctinology 123, 2600 (1988)   DOI   ScienceOn
11 Rawadi, G., Ferrer, C., SpinelIa-Jaegle, S., Roman-Roman, S., Bouali, Y. and Baron, R. : 1-(5-oxohexyI)-3,7-Dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation. Endocrinology 142, 4673 (2001)   DOI   PUBMED   ScienceOn
12 Antoni, F. A. : Molecular diversity of cyclic AMP signaling. Front Neuroendocrinol. 21, 103 (2000)   DOI   PUBMED   ScienceOn
13 Waki, Y., Horita, T., Miyamoto, K., Ohya, K. and Kasugai, S. : Ettects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and itstherapeytic effects in rat ostepenia models. Jpn. J. Pharmacol. 79, 477 (1999)   DOI   PUBMED
14 Kondo, H. Guo, J. and Bringhurst, F. R. : Cyclic adenosine monophosphate/lprotein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteopro-tegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17, 1667 (2002)   DOI   ScienceOn
15 Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M. and Chihara, K. : Prostaglandin $E_2$ stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res. 11, 62 (1996)
16 Yasuda, H., Shima，N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T : Osteoclast differentiation factor is a ligand for steoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597 (1998)